All In MedTech

FDA Clearance Tracker · P190032-S010

FoundationOne Liquid CDx (F1 Liquid CDx)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 8, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 8, 2023

Approved

Time to decision

198 days

Received Nov 22, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P190032-S010
Device name
FoundationOne Liquid CDx (F1 Liquid CDx)
Applicant location
Boston, MA
Received
Nov 22, 2022
Decided
Jun 8, 2023
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P190032

Device type

Device class
Class III

Every decision under product code PQP

FDA's approval statement

As written in FDA's record.

Approval for the FoundationOne Liquid CDx (F1 Liquid CDx). The device expands the indications for use to include a companion diagnostic indication for the detection of BRAF V600E alteration in patients with metastatic colorectal cancer (CRC) who may benefit from treatment with BRAFTOVI® (encorafenib) in combination with cetuximab.

Source documents

Other decisions for Foundation Medicine, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.